Paradigm Biopharmaceuticals Ltd has released a press release.
PAR Non-Renounceable Rights Issue Offer Booklet
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Investor Presentation - $66m Capital Raise
- Paradigm Launches $66M Capital Raising
- Paradigm provides MPS Clinical Program update
- Quarterly Update and Appendix 4C - quarterly
- Paradigm Partners with NFL Alumni Health for OA Program
Later from Paradigm Biopharmaceuticals
- 2022 Annual Report and Appendix 4E
- Successful Completion of Entitlement Offer
- Successful MPSVI Safety Review and PARA OA 008 Update
- PAR Reports Successful Primary Endpoint in Phase 2 Trial
- Paradigm Doses First UK Participant in Phase 3 Trial
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals